Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
11.91
-0.20 (-1.65%)
Dec 20, 2024, 4:00 PM EST - Market closed
Alvotech Revenue
Alvotech had revenue of $102.99M in the quarter ending September 30, 2024, with 478.60% growth. This brings the company's revenue in the last twelve months to $393.92M, up 517.92% year-over-year. In the year 2023, Alvotech had annual revenue of $93.38M with 9.84% growth.
Revenue (ttm)
$393.92M
Revenue Growth
+517.92%
P/S Ratio
7.65
Revenue / Employee
$394,313
Employees
999
Market Cap
3.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | 82.68M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organon & Co. | 6.41B |
| Perrigo Company | 4.39B |
| DENTSPLY SIRONA | 3.90B |
| Acadia Healthcare Company | 3.12B |
| ICU Medical | 2.34B |
| Sotera Health Company | 1.12B |
| PTC Therapeutics | 900.66M |
| CRISPR Therapeutics AG | 202.83M |
ALVO News
- 4 weeks ago - Alvotech's Position In The Coming Biosimilar Gold Rush - Seeking Alpha
- 5 weeks ago - Certain Closed-end Funds Advised by Franklin Templeton Fund Adviser, LLC Announce Appointment of New Chair and Directors - Business Wire
- 5 weeks ago - Alvotech (ALVO) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 - GlobeNewsWire
- 6 weeks ago - European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab) - GlobeNewsWire
- 2 months ago - Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024 - GlobeNewsWire
- 2 months ago - European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
- 2 months ago - Alvotech (ALVO) Shares Up 3.77% on Oct 2 - GuruFocus